Log In
BCIQ
Print this Print this
 

Repatha, evolocumab (AMG 145)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb against proprotein convertase subtilisin/kexin type 9 (PCSK9)
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/06/2015

Undisclosed

Undisclosed

Undisclosed

06/03/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today